[
    [
        {
            "time": "2020-08-14",
            "original_text": "药明康德中报点评：逆势增长凸显核心优势，全面布局未来可期【东吴医药朱国广团队】",
            "features": {
                "keywords": [
                    "药明康德",
                    "中报",
                    "逆势增长",
                    "核心优势",
                    "未来布局"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德中报点评：逆势增长凸显核心优势，全面布局未来可期【东吴医药朱国广团队】",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-08-14",
            "original_text": "药明康德(SH603259)：股权激励限制性股票回购注销89.79万股",
            "features": {
                "keywords": [
                    "药明康德",
                    "股权激励",
                    "回购注销",
                    "限制性股票"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德(SH603259)：股权激励限制性股票回购注销89.79万股",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-08-14",
            "original_text": "药明康德(02359-HK)中期溢利增长62.49%至人民币17.17亿元",
            "features": {
                "keywords": [
                    "药明康德",
                    "中期溢利",
                    "增长",
                    "净利润"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德(02359-HK)中期溢利增长62.49%至人民币17.17亿元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-08-14",
            "original_text": "药明康德(603259)：全面恢复 增长强劲 经调整NON-IFRS净利润增长29％",
            "features": {
                "keywords": [
                    "药明康德",
                    "全面恢复",
                    "增长强劲",
                    "NON-IFRS净利润"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德(603259)：全面恢复 增长强劲 经调整NON-IFRS净利润增长29％",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-08-14",
            "original_text": "药明康德(603259)：Q2业绩加速明显 CXO维持高景气度",
            "features": {
                "keywords": [
                    "药明康德",
                    "Q2业绩",
                    "加速",
                    "CXO",
                    "高景气度"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德(603259)：Q2业绩加速明显 CXO维持高景气度",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-08-14",
            "original_text": "【面包财报】药明康德：2020年上半年归母净利润17.17亿元，扣非净利润11.31亿元",
            "features": {
                "keywords": [
                    "药明康德",
                    "归母净利润",
                    "扣非净利润",
                    "上半年"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【面包财报】药明康德：2020年上半年归母净利润17.17亿元，扣非净利润11.31亿元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-08-14",
            "original_text": "在医药生物行业中，医药研发及生产外包(CXO)是高瓴重点布局的方向之一，包括药明康德、药明生物、泰格医药等行业龙头几乎全部被高瓴纳入怀中。",
            "features": {
                "keywords": [
                    "医药生物",
                    "CXO",
                    "高瓴资本",
                    "药明康德",
                    "行业龙头"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "在医药生物行业中，医药研发及生产外包(CXO)是高瓴重点布局的方向之一，包括药明康德、药明生物、泰格医药等行业龙头几乎全部被高瓴纳入怀中。",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-08-14",
            "original_text": "【招商医药】药明康德半年报点评：国内业务显著环比改善，客户数量快速增长",
            "features": {
                "keywords": [
                    "药明康德",
                    "半年报",
                    "国内业务",
                    "环比改善",
                    "客户数量"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【招商医药】药明康德半年报点评：国内业务显著环比改善，客户数量快速增长",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]